Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ningbo Scientz Biotechnology CoBJSE:920685 78 Return-on-Tangible-Asset is 4.88% as of Jun. 2026, which is 68% below its 10-year median of 15.49. GuruFocus rates BJSE:920685 with a GF Score™ of 78/100 and a GF Value™ of ¥16.19 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Ningbo Scientz Biotechnology Co ranks better than 68.11% on this metric.
The historical rank and industry rank for Ningbo Scientz Biotechnology Co's Return-on-Tangible-Asset or its related term are showing as below:
BJSE:920685'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.54 Med: 15.49 Max: 22.12
Current: 6.01
During the past 13 years, Ningbo Scientz Biotechnology Co's highest Return-on-Tangible-Asset was 22.12%. The lowest was 5.54%. And the median was 15.49%.
BJSE:920685's Return-on-Tangible-Asset is ranked better than 68.11% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.89
vs BJSE:920685: 6.01
Ningbo Scientz Biotechnology Co (BJSE:920685) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Ningbo Scientz Biotechnology Co Return-on-Tangible-Asset Related Terms
Ningbo Scientz Biotechnology Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ningbo Scientz Biotechnology Co Return-on-Tangible-Asset Chart
BJSE:920685 vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Ningbo Scientz Biotechnology Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ningbo Scientz Biotechnology Co Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ningbo Scientz Biotechnology Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Ningbo Scientz Biotechnology Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 4.88% mean?
Ningbo Scientz Biotechnology Co (BJSE:920685) has a Return-on-Tangible-Asset of 4.88% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Ningbo Scientz Biotechnology Co and its competitors. This is 68% below median its historical median of 15.49. Over the past decade, Ningbo Scientz Biotechnology Co's Return-on-Tangible-Asset has ranged from 5.54 to 22.12. According to the industry distribution chart, Ningbo Scientz Biotechnology Co ranks #272 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 31.9%.
Is Ningbo Scientz Biotechnology Co's Return-on-Tangible-Asset too high?
Ningbo Scientz Biotechnology Co's current Return-on-Tangible-Asset of 4.88% is 68% below median its 10-year median of 15.49. Over the past 10 years, this metric has ranged from a low of 5.54 to a high of 22.12. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.89. Ningbo Scientz Biotechnology Co's value of 4.88% is 448.3% above this industry median. Based on the distribution chart, Ningbo Scientz Biotechnology Co ranks #272 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Ningbo Scientz Biotechnology Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ningbo Scientz Biotechnology Co's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Ningbo Scientz Biotechnology Co ranks #272 out of 853 companies for Return-on-Tangible-Asset. This puts Ningbo Scientz Biotechnology Co in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.89. Ningbo Scientz Biotechnology Co's value of 4.88% is 448.3% above this benchmark. Historically, Ningbo Scientz Biotechnology Co's own Return-on-Tangible-Asset has ranged from 5.54 to 22.12 over the past decade. While the company's 10-year median is 15.49 vs. the industry median of 0.89, Ningbo Scientz Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.89, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ningbo Scientz Biotechnology Co's current Return-on-Tangible-Asset of 4.88% is 448.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Ningbo Scientz Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ningbo Scientz Biotechnology Co's current Return-on-Tangible-Asset is 4.88%, which is 68% below median its own 10-year median of 15.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningbo Scientz Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Ningbo Scientz Biotechnology Co (BJSE:920685) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥16.19, compared to a current price of ¥12.10 — trading 25.3% below its estimated fair value. The current Return-on-Tangible-Asset is 4.88%, which is 68% below median its 10-year median of 15.49 and 448.3% above the Medical Devices & Instruments industry median of 0.89. Ningbo Scientz Biotechnology Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Ningbo Scientz Biotechnology Co (BJSE:920685), the current Return-on-Tangible-Asset is 4.88% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ningbo Scientz Biotechnology Co (BJSE:920685) Overvalued in 2026?
Based on GuruFocus' analysis, Ningbo Scientz Biotechnology Co stock appears to be undervalued.
The current stock price of ¥12.10 is trading 25.3% below its estimated GF Value™ of ¥16.19.
GuruFocus considers Ningbo Scientz Biotechnology Co to be Modestly Undervalued.
Key valuation signals for BJSE:920685:
Return-on-Tangible-Asset: 4.88% (68% below median its 10-year median of 15.49)
GF Value™: ¥16.19 vs. price of ¥12.10 (25.3% below fair value)
Industry Position: 448.3% above the Medical Devices & Instruments median (#272 of 853)
No single metric tells the full story. See the BJSE:920685 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920685 has been successfully added to your 
